Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

Fineline Cube Aug 19, 2026
Company Drug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Fineline Cube Aug 19, 2026
Company Drug

Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME

Fineline Cube May 23, 2023

US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of...

Company Deals

Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies

Fineline Cube May 23, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Policy / Regulatory

NHSA Proposes Draft to Enhance Basic Medical Insurance Payment Management for Consumables

Fineline Cube May 23, 2023

The National Healthcare Security Administration (NHSA) has issued a Notice seeking public feedback on draft...

Company Drug

SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody

Fineline Cube May 23, 2023

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products...

Policy / Regulatory

China Aims to Establish Basic Elderly Care System by 2025, Outlines Comprehensive Plan

Fineline Cube May 23, 2023

The General Office of the CPC Central Committee and General Office of the State Council...

Company Deals

JW Therapeutics Secures Supply Agreement with Juno to Advance CAR-T Therapy Commercialization

Fineline Cube May 22, 2023

China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno,...

Company Drug

HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study

Fineline Cube May 22, 2023

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the...

Company Deals

GenScript Biotech’s Legend Biotech Secures Private Placement with Hillhouse Investment

Fineline Cube May 22, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that its subsidiary,...

Company Drug

Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials

Fineline Cube May 22, 2023

Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates

Fineline Cube May 22, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National...

Company Drug

Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC

Fineline Cube May 22, 2023

Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...

Policy / Regulatory

Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement

Fineline Cube May 22, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in...

Company

Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase

Fineline Cube May 22, 2023

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first...

Company Drug

Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy

Fineline Cube May 19, 2023

US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...

Company Deals

MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange

Fineline Cube May 19, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin...

Company Deals

Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy

Fineline Cube May 19, 2023

US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...

Company Deals

Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal

Fineline Cube May 19, 2023

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...

Company Deals

International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements

Fineline Cube May 19, 2023

The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development...

Company Medical Device

MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System

Fineline Cube May 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches

Fineline Cube May 19, 2023

A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a...

Posts pagination

1 … 567 568 569 … 710

Recent updates

  • Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance
  • Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes
  • Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division
  • Nhwa Pharmaceutical Wins NMPA IND Approval for Two Category 1 Chemical Drugs – NH130 for Schizophrenia & Alzheimer’s Psychosis, NH302 for Acute Pain
  • CSPC Pharmaceutical’s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First‑Line Advanced Breast Cancer – HER2 Bispecific Combo Advances in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

Company Drug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Company

Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division

Company Drug

Nhwa Pharmaceutical Wins NMPA IND Approval for Two Category 1 Chemical Drugs – NH130 for Schizophrenia & Alzheimer’s Psychosis, NH302 for Acute Pain

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.